Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?

Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015

(2018) Matthew J. Crowley et al.   DIABETES OBESITY & METABOLISM

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients

(2017) Fei Wang et al.   MEDICINE

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

(2017) Christoph Wanner et al.   CIRCULATION

Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline

(2016) A. M. Hung et al.   Clinical Journal of the American Society of Nephrology

Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus

(2016) Tim Heise et al.   CLINICAL THERAPEUTICS

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

(2016) Tim Heise et al.   CLINICAL THERAPEUTICS

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study

(2016) Manuj Sharma et al.   BMJ Open

Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014

(2016) Diana Hedevang Christensen et al.   Clinical Epidemiology

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

(2015) R. Chilton et al.   DIABETES OBESITY & METABOLISM

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

(2015) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

(2015) Ele Ferrannini et al.   EUROPEAN HEART JOURNAL

Association of Cardiometabolic Multimorbidity With Mortality

(2015) Emanuele Di Angelantonio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Antidiabetic Drugs in the U.S., 2003–2012

(2014) Christian Hampp et al.   DIABETES CARE

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011

(2013) Takahide Kohro et al.   International Heart Journal

Kidney Disease and Increased Mortality Risk in Type 2 Diabetes

(2013) M. Afkarian et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

(2012) Adriana M. Hung et al.   KIDNEY INTERNATIONAL

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)

(2010) Erland ERDMANN et al.   Journal of Diabetes

Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies

(2008) A. D. Rao et al.   DIABETES CARE

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE